Cargando…

Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan

Patients with diabetes are at increased risk of cancer development and osteoporosis. Metformin is an effective agent for diabetes management. Epidemiological studies have identified an association between metformin use and cancer prevention. This article outlines the potential for metformin to atten...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chieh-Hua, Chung, Chi-Hsiang, Kuo, Feng-Chih, Chen, Kuan-Chan, Chang, Chia-Hao, Kuo, Chih-Chun, Lee, Chien-Hsing, Su, Sheng-Chiang, Liu, Jhih-Syuan, Lin, Fu-Huang, Tsao, Chang-Huei, Hsieh, Po-Shiuan, Hung, Yi-Jen, Hsieh, Chang-Hsun, Chien, Wu-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565460/
https://www.ncbi.nlm.nih.gov/pubmed/32887312
http://dx.doi.org/10.3390/jcm9092839
_version_ 1783595937605615616
author Lu, Chieh-Hua
Chung, Chi-Hsiang
Kuo, Feng-Chih
Chen, Kuan-Chan
Chang, Chia-Hao
Kuo, Chih-Chun
Lee, Chien-Hsing
Su, Sheng-Chiang
Liu, Jhih-Syuan
Lin, Fu-Huang
Tsao, Chang-Huei
Hsieh, Po-Shiuan
Hung, Yi-Jen
Hsieh, Chang-Hsun
Chien, Wu-Chien
author_facet Lu, Chieh-Hua
Chung, Chi-Hsiang
Kuo, Feng-Chih
Chen, Kuan-Chan
Chang, Chia-Hao
Kuo, Chih-Chun
Lee, Chien-Hsing
Su, Sheng-Chiang
Liu, Jhih-Syuan
Lin, Fu-Huang
Tsao, Chang-Huei
Hsieh, Po-Shiuan
Hung, Yi-Jen
Hsieh, Chang-Hsun
Chien, Wu-Chien
author_sort Lu, Chieh-Hua
collection PubMed
description Patients with diabetes are at increased risk of cancer development and osteoporosis. Metformin is an effective agent for diabetes management. Epidemiological studies have identified an association between metformin use and cancer prevention. This article outlines the potential for metformin to attenuate the rate of osteoporosis in diabetic patients with carcinoma in situ (CIS). From the National Health Insurance Research Database of Taiwan, 7827 patients with diabetes with CIS who were receiving metformin therapy were selected, along with 23,481 patients as 1:3 sex-, age- and index year-matched controls, who were not receiving metformin therapy. A Cox proportional hazard analysis was used to compare the rate of osteoporosis during an average of 15-year follow-up. Of the subjects who were enrolled, 801 (2.56%) had osteoporosis, including 168 from the metformin group (2.15%) and 633 from the without metformin group (2.70%). The metformin group presented a lower rate of osteoporosis at the end of follow-up (p = 0.009). The Cox proportional hazard regression analysis revealed a lower rate of osteoporosis for the metformin group (adjusted hazard ratio of 0.820; 95% confidence interval = 0.691–0.972, p = 0.022). Diabetic patients with CIS under metformin therapy presented lower osteoporosis rate than those who were not receiving metformin therapy.
format Online
Article
Text
id pubmed-7565460
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75654602020-10-26 Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan Lu, Chieh-Hua Chung, Chi-Hsiang Kuo, Feng-Chih Chen, Kuan-Chan Chang, Chia-Hao Kuo, Chih-Chun Lee, Chien-Hsing Su, Sheng-Chiang Liu, Jhih-Syuan Lin, Fu-Huang Tsao, Chang-Huei Hsieh, Po-Shiuan Hung, Yi-Jen Hsieh, Chang-Hsun Chien, Wu-Chien J Clin Med Article Patients with diabetes are at increased risk of cancer development and osteoporosis. Metformin is an effective agent for diabetes management. Epidemiological studies have identified an association between metformin use and cancer prevention. This article outlines the potential for metformin to attenuate the rate of osteoporosis in diabetic patients with carcinoma in situ (CIS). From the National Health Insurance Research Database of Taiwan, 7827 patients with diabetes with CIS who were receiving metformin therapy were selected, along with 23,481 patients as 1:3 sex-, age- and index year-matched controls, who were not receiving metformin therapy. A Cox proportional hazard analysis was used to compare the rate of osteoporosis during an average of 15-year follow-up. Of the subjects who were enrolled, 801 (2.56%) had osteoporosis, including 168 from the metformin group (2.15%) and 633 from the without metformin group (2.70%). The metformin group presented a lower rate of osteoporosis at the end of follow-up (p = 0.009). The Cox proportional hazard regression analysis revealed a lower rate of osteoporosis for the metformin group (adjusted hazard ratio of 0.820; 95% confidence interval = 0.691–0.972, p = 0.022). Diabetic patients with CIS under metformin therapy presented lower osteoporosis rate than those who were not receiving metformin therapy. MDPI 2020-09-02 /pmc/articles/PMC7565460/ /pubmed/32887312 http://dx.doi.org/10.3390/jcm9092839 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lu, Chieh-Hua
Chung, Chi-Hsiang
Kuo, Feng-Chih
Chen, Kuan-Chan
Chang, Chia-Hao
Kuo, Chih-Chun
Lee, Chien-Hsing
Su, Sheng-Chiang
Liu, Jhih-Syuan
Lin, Fu-Huang
Tsao, Chang-Huei
Hsieh, Po-Shiuan
Hung, Yi-Jen
Hsieh, Chang-Hsun
Chien, Wu-Chien
Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan
title Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan
title_full Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan
title_fullStr Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan
title_full_unstemmed Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan
title_short Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan
title_sort metformin attenuates osteoporosis in diabetic patients with carcinoma in situ: a nationwide, retrospective, matched-cohort study in taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565460/
https://www.ncbi.nlm.nih.gov/pubmed/32887312
http://dx.doi.org/10.3390/jcm9092839
work_keys_str_mv AT luchiehhua metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT chungchihsiang metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT kuofengchih metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT chenkuanchan metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT changchiahao metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT kuochihchun metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT leechienhsing metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT sushengchiang metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT liujhihsyuan metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT linfuhuang metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT tsaochanghuei metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT hsiehposhiuan metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT hungyijen metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT hsiehchanghsun metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan
AT chienwuchien metforminattenuatesosteoporosisindiabeticpatientswithcarcinomainsituanationwideretrospectivematchedcohortstudyintaiwan